A 28-year-old Redditor has $340,000 saved, with part of the money coming from an inheritance and part of the money coming ...

EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiplesolid tumors -- ...

Data demonstrate potential superiority of antibody-based T cell engager CDR404 over TCR-based approaches, consistent with emerging Phase 1 trial signals of ...

Texas A&M University-Central Texas hosted its annual Student Research Symposium earlier this month, when undergraduate and ...

Dr. Stephen Hauser was a young resident at Harvard when he met his first patient with multiple sclerosis, a woman with a thriving professional life who’d been completely wiped out by her condition, ...

UC Davis student Natasha Bibbs of Sacramento has already gone places with academic research — and she hopes to go even ...

Researchers with City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U ...

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel targ ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

TAL61 demonstrated significant anti-tumor properties with strong tolerability in patient-derived xenograft models of chordoma TAL61 showed robust single-agent activity in Brachyury-positive non-small ...

Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical modelsAnti-IL1RAP ADC targets IL1RAP, which is overexpressed in many tumors and their tumor microenvironm ...

Faculty members Rebecca Som Castellano and Lisa Meierotto recently traveled with student and research assistant Alice Mwamba ...